randomly assigned 55 patients with biopsy-confirmed NASH and either impaired glucose tolerance or type 2 diabetes to receive a hypocaloric diet plus either pioglitazone (30 mg daily for 2 months ...

Nonalcoholic steatohepatitis (NASH) is an increasingly common cause of chronic liver disease worldwide. Currently, no specific pharmacologic therapy has been shown to treat NASH effectively.

US-based Mylan Pharmaceuticals gained FDA approval for 15 milligram, 30 mg and ... and strength as brand-name drugs. As with the brand-name drug, Mylan’s generic version of Actos will carry ...